Improved Survival with a Chemotherapy Free Option for EGFR Mutated Lung Cancer
Living with advanced non–small cell lung cancer (NSCLC) driven by mutations in the EGFR gene can feel overwhelming. For many patients, treatment has meant targeted therapy with the gold standard osimertinib, an oral targeted therapy directed toward the EGFR mutated tumor cells. Data from the large MARIPOSA trial published in September 2025 in The New […]
A New Era in Bladder Cancer Treatment: Targeted Therapy Offers Hope – Daniel Chong, MD, Virginia Cancer Specialists
Bladder cancer, though not as widely discussed as some other cancers, is a significant health concern worldwide. With approximately 82,000 new cases each year, and sadly, 16,700 annual deaths attributed to it, it demands attention and innovative solutions. Fortunately, advancements in medical science have led to a greater understanding of bladder cancer and improved […]
Advancements in Colorectal Cancer Treatment: Insights from Samuel Lee, MD at Virginia Cancer Specialists
The treatment paradigm for colorectal cancer is continuously evolving towards more personalized treatment plans. With more research conducted over the past decade, we are transitioning away from a one-size-fits-all approach to more individualized treatments for all stages of colorectal cancer. Early and Locally Advanced Colon Cancer: Upfront surgery remains the mainstay of treatment. Treatment after […]
Brentuximab Vedotin: A Promising Frontline Therapy for Older Hodgkin Lymphoma Patients
A recent study published by Dr. Dipti Patel-Donnelly, of Virginia Cancer Specialists and colleagues has shed light on a groundbreaking approach in the treatment of advanced-stage classical Hodgkin lymphoma (cHL) in older patients. This noncomparative phase 2 study, detailed in the research article here, explores the efficacy of brentuximab vedotin (BV) in combination with dacarbazine […]
New Advances in Early-Stage Lung Cancer Treatment – Samantha DiBenedetto, MD
Lung cancer poses a significant healthcare challenge in the United States, with approximately 237,000 individuals newly diagnosed each year. Although the majority of cases are found at an advanced stage, approximately 25-35% of cases are detected early where surgery and chemotherapy can be effective treatment options. Despite these efforts, disease recurrence rates remain high, impacting […]
Advancements in Treating Chemotherapy Side Effects – A New Standard of Care for Preventing Hand-Foot Syndrome – Igryl S. Cordero, MD
Patients undergoing treatment for breast or gastrointestinal cancers with the chemotherapy drug capecitabine (Xeloda®) may develop hand-foot syndrome (HFS). A common treatment side-effect, HFS can lead to redness, swelling, skin peeling, and sometimes painful blisters on the palms and soles. Although the syndrome is not life-threatening, it can cause significant discomfort and negatively impact a […]
Landmark Non-Small Cell Lung Cancer Study – Clinically Meaningful Improvement and Progression Free Survival, Alexander I. Spira, MD, PhD, FACP
Virginia Cancer Specialists Research Institute – Landmark “Non-Small Cell Lung Cancer Study” – Alexander I. Spira, MD, PhD, FACP Planned interim overall survival analysis showed a trend favoring the combination of RYBREVANT® and lazertinib compared to osimertinib* First pivotal study to show a clinically meaningful benefit in a chemotherapy-free regimen versus osimertinib – See the […]